Capital Flow Monitor · Sponsors · CIK 1814509
Trailhead Biosystems Inc.
23215 COMMERCE PARK ROAD, BEACHWOOD, OH, 44122 · 220-222-9142
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$40.6M
Sold
$40.6M
% sold
100.0%
Investors
7
Min investment
$50K
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-30 | D/A ·current | 506(b) | $40.6M | $40.6M | 100.0% | 7 | EDGAR ↗ |
| 2026-07-30 | D/A | 506(b) | $40.4M | $40.4M | 100.0% | 7 | EDGAR ↗ |
| 2026-01-05 | D/A | 506(b) | $20.0M | $20.0M | 100.0% | 4 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- David Llewellyn — Executive Officer / Director, Beachwood, OH
-
Craig Nemiroff — Director, Beachwood, OH
1 other raise
- Noveome Biotherapeutics, Inc. $6.8M of $15.0M · 45.0%
- Joshua Snow — Executive Officer, Beachwood, OH
- Wolfgang Hofmann — Director, Beachwood, OH
-
Houman Hemmati — Director, Beachwood, OH
1 other raise
- Noveome Biotherapeutics, Inc. $6.8M of $15.0M · 45.0%
- Divya Trivedi — Executive Officer, Beachwood, OH
-
Michael Kaufman — Executive Officer / Director, Beachwood, OH
3 other raises
- Noveome Biotherapeutics, Inc. $6.8M of $15.0M · 45.0%
- MAK One Fund LP $894.9M of —
- MAK Capital International Ltd $57.4M of —
- Jan Jensen — Director, Beachwood, OH
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.